FOLD Q2 2023 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$95M+17.1% YoY

Gross Profit

$85M90.4% margin

Operating Income

-$19M-20.0% margin

Net Income

-$43M-45.7% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$18M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$730M

Total Liabilities

$619M

Stockholders' Equity

$112M

Cash & Equivalents

$211M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$95M	$81M	+17.1%
Gross Profit	$85M	$73M	+17.7%
Operating Income	-$19M	-$61M	+68.9%
Net Income	-$43M	-$62M	+30.4%

Geographic Segments

Non-US

$57M61%

UNITED STATES

$37M39%